Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  He, Zhengxiang ^a   Chen, Lili ^a   Souto, Fabricio O ^a   Canasto Chibuque, Claudia ^a   Bongers, Gerold ^a   Deshpande, Madhura ^a   Harpaz, Noam ^a   Ko, Huaibin M ^a   Kelley, Kevin ^a   Furtado, Glaucia C ^a   Lira, Sergio A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMATOUS POLYPOSIS COLI PROTEIN, MOUSE; APC PROTEIN; CYTOKINE; IL33 PROTEIN, HUMAN; IL33 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33;

ANIMAL; CELL CULTURE; CELL TRANSFORMATION; CYTOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INTESTINE TUMOR; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; MOUSE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH2 CELL; TRANSGENIC MOUSE; UPREGULATION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYTOKINES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; INTESTINAL NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; UP-REGULATION;

EID: 85024366883     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-05716-z     Document Type: Article

References (71)

1. Baekkevold, E. S. et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163, 69-79, doi:10.1016/S0002-9440(10)63631-0 (2003).
2. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490, doi:10.1016/j.immuni.2005.09.015 (2005).
3. Chackerian, A. A. et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. Journal of immunology 179, 2551-2555 (2007).
4. Greenfeder, S. A. et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. The Journal of biological chemistry 270, 13757-13765 (1995).
5. Ohno, T., Morita, H., Arae, K., Matsumoto, K. & Nakae, S. Interleukin-33 in allergy. Allergy 67, 1203-1214, doi:10.1111/all.12004 (2012).
6. Mirchandani, A. S., Salmond, R. J. & Liew, F. Y. Interleukin-33 and the function of innate lymphoid cells. Trends in immunology 33, 389-396, doi:10.1016/j.it.2012.04.005 (2012).
7. Lu, J., Kang, J., Zhang, C. & Zhang, X. The role of IL-33/ST2L signals in the immune cells. Immunol Lett 164, 11-17, doi:10.1016/j. imlet.2015.01.008 (2015).
8. Liew, F. Y., Pitman, N. I. & McInnes, I. B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature reviews. Immunology 10, 103-110, doi:10.1038/nri2692 (2010).
9. Beltran, C. J. et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflammatory bowel diseases 16, 1097-1107, doi:10.1002/ibd.21175 (2010).
10. Seidelin, J. B. et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 128, 80-85, doi:10.1016/J.Imlet.2009.11.001 (2010).
11. Pastorelli, L. et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proceedings of the National Academy of Sciences of the United States of America 107, 8017-8022, doi:10.1073/ pnas.0912678107 (2010).
12. Kobori, A. et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45, 999-1007, doi:10.1007/S00535-010-0245-1 (2010).
13. Sedhom, M. A. K. et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62, 1714-1723, doi:10.1136/Gutjnl-2011-301785 (2013).
14. Sponheim, J. et al. Inflammatory Bowel Disease-Associated Interleukin-33 Is Preferentially Expressed in Ulceration-Associated Myofibroblasts. Am J Pathol 177, 2804-2815, doi:10.2353/Ajpath.2010.100378 (2010).
15. Gundersen, M. D. et al. Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis. Scientific reports 6, 35403, doi:10.1038/srep35403 (2016).
16. Droste, J. S. T. S. et al. Diagnostic yield of colorectal neoplasia in daily clinical practice: consequences for future colorectal cancer screening? Eur J Gastroen Hepat 21, A37-A38 (2009).
17. Erreni, M., Mantovani, A. & Allavena, P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer microenvironment: official journal of the International Cancer Microenvironment Society 4, 141-154, doi:10.1007/s12307-010-0052-5 (2011).
18. Oshima, M. et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proceedings of the National Academy of Sciences of the United States of America 92, 4482-4486 (1995).
19. Moser, A. R., Pitot, H. C. & Dove, W. F. A Dominant Mutation That Predisposes to Multiple Intestinal Neoplasia in the Mouse. Science 247, 322-324, doi:10.1126/Science.2296722 (1990).
20. Luthi, A. U. et al. Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases. Immunity 31, 84-98, doi:10.1016/J.Immuni.2009.05.007 (2009).
21. Pastorelli, L., De Salvo, C., Vecchi, M. & Pizarro, T. T. The role of IL-33 in gut mucosal inflammation. Mediators of inflammation 2013, 608187, doi:10.1155/2013/608187 (2013).
22. Pastorelli, L., De Salvo, C., Cominelli, M. A., Vecchi, M. & Pizarro, T. T. Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therapeutic advances in gastroenterology 4, 311-323, doi:10.1177/1756283X11410770 (2011).
23. Nunes, T., Bernardazzi, C. & de Souza, H. S. Interleukin-33 and inflammatory bowel diseases: lessons from human studies. Mediators of inflammation 2014, 423957, doi:10.1155/2014/423957 (2014).
24. Lopetuso, L. R., Chowdhry, S. & Pizarro, T. T. Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Frontiers in immunology 4, 181, doi:10.3389/fimmu.2013.00181 (2013).
25. Maywald, R. L. et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proceedings of the National Academy of Sciences of the United States of America 112, E2487-2496, doi:10.1073/pnas.1422445112 (2015).
26. Mertz, K. D. et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology 5, e1062966, doi:10.1080/2162402X.2015.1062966 (2016).
27. Malik, A. et al. IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis. The Journal of clinical investigation, doi:10.1172/JCI88625 (2016).
28. Chen, L. et al. IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal immunology 8, 390-402, doi:10.1038/mi.2014.77 (2015).
29. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281-2308, doi:10.1038/nprot.2013.143 (2013).
30. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. The Journal of experimental medicine 191, 1069-1076 (2000).
31. Espinassous, Q. et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. Journal of immunology 183, 1446-1455, doi:10.4049/jimmunol.0803067 (2009).
32. Kurowska-Stolarska, M. et al. IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation. Journal of immunology 183, 6469-6477, doi:10.4049/Jimmunol.0901575 (2009).
33. Joshi, A. D. et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. Bmc Immunol 11, doi:Artn 52, doi:10.1186/1471-2172-11-52 (2010).
34. Sansom, O. J. et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes & development 18, 1385-1390, doi:10.1101/gad.287404 (2004).
35. Duerkop, B. A., Vaishnava, S. & Hooper, L. V. Immune Responses to the Microbiota at the Intestinal Mucosal Surface. Immunity 31, 368-376, doi:10.1016/J.Immuni.2009.08.009 (2009).
36. Bongers, G. et al. Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. The Journal of experimental medicine 211, 457-472, doi:10.1084/jem.20131587 (2014).
37. Dennis, K. L. et al. Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer research 73, 5905-5913, doi:10.1158/0008-5472.CAN-13-1511 (2013).
38. Latiano, A. et al. Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. PloS one 8, doi:ARTN e62144, doi:10.1371/journal.pone.0062144 (2013).
39. Duan, L. H. et al. Interleukin-33 Ameliorates Experimental Colitis through Promoting Th2/Foxp3(+) Regulatory T-Cell Responses in Mice. Mol Med 18, 753-761, doi:10.2119/Molmed.2011.00428 (2012).
40. Waddell, A. et al. IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function. Inflammatory bowel diseases 21, 2737-2746, doi:10.1097/MIB.0000000000000532 (2015).
41. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proceedings of the National Academy of Sciences of the United States of America 107, 18581-18586, doi:10.1073/Pnas.1003059107 (2010).
42. Imaeda, H. et al. Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodiuminduced colitis. Int J Mol Med 28, 573-578, doi:10.3892/Ijmm.2011.718 (2011).
43. Gross, P., Doser, K., Falk, W., Obermeier, F. & Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflammatory bowel diseases 18, 1900-1909, doi:10.1002/Ibd.22900 (2012).
44. Pushparaj, P. N. et al. Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140, 70-77, doi:10.1111/ imm.12111 (2013).
45. Yang, Z. et al. IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent. American journal of physiology. Gastrointestinal and liver physiology 304, G381-389, doi:10.1152/ajpgi.00357.2012 (2013).
46. Seidelin, J. B. et al. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J Gastroenterol 50, 180-190, doi:10.1007/s00535-014-0982-7 (2015).
47. Monticelli, L. A. et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proceedings of the National Academy of Sciences of the United States of America 112, 10762-10767, doi:10.1073/ pnas.1509070112 (2015).
48. Yang, Q. et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. European journal of immunology 41, 3351-3360, doi:10.1002/eji.201141629 (2011).
49. Ngoi, S. M. et al. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proceedings of the National Academy of Sciences of the United States of America 109, 10486-10491, doi:10.1073/pnas.1202607109 (2012).
50. Gao, K. et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer letters 335, 463-471, doi:10.1016/j.canlet.2013.03.002 (2013).
51. Gao, X. et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. Journal of immunology 194, 438-445, doi:10.4049/jimmunol.1401344 (2015).
52. Jovanovic, I. P. et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. International journal of cancer. Journal international du cancer 134, 1669-1682, doi:10.1002/ijc.28481 (2014).
53. Liu, X. et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochemical and biophysical research communications 453, 486-492, doi:10.1016/j.bbrc.2014.09.106 (2014).
54. Meinicke, H. et al. Tumor-associated changes in intestinal epithelial cells cause local accumulation of KLRG1+ GATA3+ regulatory T cells in mice. Immunology, doi:10.1111/imm.12750 (2017).
55. Biton, J. et al. In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. J Immunol 197, 1708-1719, doi:10.4049/jimmunol.1502124 (2016).
56. Siede, J. et al. IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGFbeta Release. PloS one 11, e0161507, doi:10.1371/journal.pone.0161507 (2016).
57. Isidro, R. A. & Appleyard, C. B. Colonic macrophage polarization in homeostasis, inflammation, and cancer. American journal of physiology. Gastrointestinal and liver physiology 311, G59-73, doi:10.1152/ajpgi.00123.2016 (2016).
58. Seo, D. H. et al. Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. Scientific reports 7, 851, doi:10.1038/s41598-017-00840-2 (2017).
59. Tu, L. et al. IL-33-induced alternatively activated macrophage attenuates the development of TNBS-induced colitis. Oncotarget 8, 27704-27714, doi:10.18632/oncotarget.15984 (2017).
60. Fang, M. et al. IL-33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer research. doi:10.1158/0008-5472.CAN-16-1602 (2017).
61. Hooper, L. V., Stappenbeck, T. S., Hong, C. V. & Gordon, J. I. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nature immunology 4, 269-273, doi:10.1038/ni888 (2003).
62. Forman, R. A. et al. The Goblet Cell Is the Cellular Source of the Anti-Microbial Angiogenin 4 in the Large Intestine Post Trichuris muris Infection. PloS one 7, doi:ARTN e42248, doi:10.1371/journal.pone.0042248 (2012).
63. Steppan, C. M. et al. A family of tissue-specific resistin-like molecules. Proceedings of the National Academy of Sciences of the United States of America 98, 502-506, doi:10.1073/pnas.98.2.502 (2001).
64. Artis, D. et al. RELM beta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proceedings of the National Academy of Sciences of the United States of America 101, 13596-13600, doi:10.1073/pnas.0404034101 (2004).
65. Hung, L. Y. et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proceedings of the National Academy of Sciences of the United States of America 110, 282-287, doi:10.1073/pnas.1206587110 (2013).
66. Burger-van Paassen, N. et al. Mucin Muc2 deficiency and weaning influences the expression of the innate defense genes Reg3beta, Reg3gamma and angiogenin-4. PloS one 7, e38798, doi:10.1371/journal.pone.0038798 (2012).
67. Gounaris, E. et al. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer research 69, 5490-5497, doi:10.1158/0008-5472.CAN-09-0304 (2009).
68. Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123, doi:10.1126/ science.1224820 (2012).
69. Pinto, D., Robine, S., Jaisser, F., El Marjou, F. & Louvard, D. Regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of small and large intestines. Journal of Biological Chemistry 274, 6476-6482, doi:10.1074/Jbc.274.10.6476 (1999).
70. Mashiko, D. et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Scientific reports 3, 3355, doi:10.1038/srep03355 (2013).
71. Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine 4, 844-847 (1998).